english.prescrire.org > Spotlight > Archives : 2015 > In the October issue of Prescrire International: Regorafenib (Stivarga°) and gastrointestinal stromal tumours after treatment failure

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2015 : 1 | 30 | 60

In the October issue of Prescrire International: Regorafenib (Stivarga°) and gastrointestinal stromal tumours after treatment failure

FREE DOWNLOAD In this sample page from the New Products section: regorafenib has no proven impact on overall survival for patients with unresectable or metastatic gastrointestinal stromal tumours in whom imatinib and sunitinib have failed.
Full text available for free download.

Summary

  • Regorafenib (Stivarga°, Bayer Pharma) inhibits tyrosine kinases involved in angiogenesis and tumour growth. It has been authorised for patients with unresectable or metastatic gastrointestinal stromal tumours after failure of imatinib and sunitinib.

  • Regorafenib had no impact on overall survival in a placebo-controlled trial in 199 patients, but adverse effects were frequent and serious.
     
  • Symptomatic care is a more reasonable choice.

Full text available for free download.

 ©Prescrire 1 October 2015

"Regorafenib (Stivarga°) and gastrointestinal stromal tumours after treatment failure" Prescrire Int 2015; 24 (164): 234. (Pdf, free)
Download the full review
Pdf, free